Skip to main content

RRX001-33 REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

NCT03699956

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

EpicentRx

This study will compare the imapct of the addition of the study drug, RRx-001, to 'platinum doublet' chemotherapy versus platinum doublet chemotherapy alone that is third-line or beyond.